Bill brief/S272/119th Congress
Formula makers would have to report confirmed contamination within 1 business day
Official title
Protect Infant Formula from Contamination Act
This bill changes federal food safety law to require faster reporting and stronger follow‑up when infant formula tests positive for dangerous microorganisms. It also requires regular federal reports and planning to track and strengthen the infant formula supply. The Food and Drug Administration (FDA) and other agencies would take on new monitoring and coordination duties if this bill becomes law.
Bill
S272
Introduced
Date not available
Sponsor
Sponsor not listed
Chamber
Senate
What the bill does
What this bill does
The bill updates the Federal Food, Drug, and Cosmetic Act to set clear timelines and steps when infant formula may be unsafe. If a manufacturer knows about a problem with an infant formula, it must now notify the Secretary of Health and Human Services within one business day, instead of just “promptly.
” If any required finished‑product test comes back with a confirmed positive result for a harmful microorganism, the manufacturer must tell the Secretary within one business day, work with the Secretary to isolate and, if required, stop distributing and dispose of the affected product, and send detailed test results or genetic data from the positive sample to the Secretary. The bill also requires the Secretary to act quickly in response.
Within one business day after getting a positive‑test notification, the Secretary must respond to the manufacturer to start talks about investigation and corrective actions and share findings as appropriate. Within 90 days of any safety notification, the Secretary must confirm, using documentation from the manufacturer, that an appropriate investigation and any needed corrective actions are being done. The Secretary must review the testing methods and the risk of cross‑contamination during testing, and the manufacturer must make its records available electronically and for inspection.
Beyond contamination events, the bill creates several new reporting duties to improve both safety and supply of infant formula. Within 180 days of enactment, the Secretary must issue a progress report on putting into place the recommendations from FDA’s January 2025 report on making the U. S. infant formula market more resilient, including stating what extra powers or resources may be needed. Starting within 270 days of enactment, and then at least every quarter for five years, the Secretary must send Congress reports on key infant formula supply‑chain data, such as in‑stock rates.
The Secretary must also consult with the Department of Agriculture and other agencies on short‑term and long‑term efforts. At 1, 3, and 5 years after enactment, the Secretary must work with public stakeholders and manufacturers to identify evidence‑based practices to maximize formula supply and safety, and report to Congress on practice changes that could improve both.
Key provisions
- Formula makers would have to report certain problems within one business day. This replaces the older rule that only told them to report problems "promptly."
- A confirmed positive test in finished formula would have to be reported within one business day. This applies to harmful germs already covered by FDA finished-product testing rules.
- Companies would have to work with the Secretary to isolate the affected formula. If required, they would have to stop selling it and dispose of contaminated formula properly.
- Companies would have to share the test results from confirmed positive samples. They would also have to share either germ samples or whole-genome sequence data, meaning detailed genetic information from the germ.
- The Secretary would have to respond within one business day after getting a positive-test notice. That response would start talks about the investigation and needed fixes.
- Within 90 days of any safety notice, the Secretary would have to check company documents. Those documents must show that the company has done, or is doing, a proper search for the cause and needed fixes.
- Each cause review would have to look at the lab test methods. It would also have to check whether the sample may have been contaminated during testing.
- Within 180 days, the Secretary would have to report progress on FDA's January 2025 report, "Long-Term National Strategy to Increase the Resiliency of the U.S. Infant Formula Market." The report must also say whether new powers or resources are needed.
- The Secretary would have to send Congress formula supply reports at least every quarter for five years. The reports must start no later than 270 days after the bill becomes law and include data such as in-stock rates.
- The Secretary would have to work with the Department of Agriculture and other agencies. They would look at urgent formula needs and long-term ways to make the market stronger.
Impact
Why it matters—and who it affects
Why it matters
Infant formula is often the main or only source of nutrition for many babies, so contamination can have serious health effects. This bill aims to reduce the chance that unsafe formula reaches families by requiring very fast reporting of positive contamination tests, clear cooperation between manufacturers and the federal government, and documented investigations and corrective actions. Faster action could help limit how much suspect product is on the market when problems are found. The bill also responds to past formula shortages by focusing on supply‑chain data and resiliency. Regular reports to Congress on in‑stock rates and other key data, along with required consultations and evidence‑based recommendations, are meant to help the federal government and industry better understand and manage risks to the infant formula supply. How much these steps would change safety outcomes or prevent shortages is not certain and would depend on how the FDA and manufacturers carry out the new duties and whether Congress provides any additional authorities or resources that are later requested.
Who it affects
This bill mainly affects babies who rely on formula, families who buy it, and companies that make it. Families could benefit if faster reporting helps keep unsafe formula off shelves. Manufacturers would face tighter deadlines, more data-sharing rules, and more follow-up after positive tests. The FDA and other federal agencies would have to track supply problems and report more often to Congress.
The debate
The case for it—and the concerns
These are the main arguments surrounding the bill, not Modern Action’s position.
Arguments in support
- Faster, specific timelines for reporting contamination can reduce delays between discovering a problem and government action, which may limit the amount of unsafe formula available to families.
- Requiring manufacturers to share detailed test data and genetic information can help FDA more accurately trace sources of contamination and improve prevention strategies.
- Mandatory confirmation that investigations and corrective actions are being done creates clearer accountability for both manufacturers and regulators.
- Regular supply‑chain and in‑stock reporting to Congress can improve oversight and help detect and address shortages earlier.
- Drawing on an existing FDA long‑term strategy and requiring evidence‑based practices encourages data‑driven improvements rather than ad hoc responses.
- Formal coordination with the Department of Agriculture and other agencies can align safety and supply efforts across programs that serve infants, such as WIC.
- Periodic reviews at 1, 3, and 5 years allow adjustments over time as more is learned about effective ways to protect both safety and supply.
Concerns and tradeoffs
- Tighter reporting deadlines and additional documentation requirements may increase administrative and compliance costs for formula manufacturers, which could affect smaller producers more.
- Requirements to promptly cease distribution and dispose of product after positive tests, under federal direction, could lead to large product losses, which some may fear could worsen short‑term supply issues in certain situations.
- Frequent federal reporting and consultation duties may strain FDA resources if not matched with additional funding or staff, potentially affecting oversight in other areas.
- Some may view the new mandates as duplicating or complicating existing food safety regulations rather than simplifying them.
- Sharing detailed testing and genetic data with the government might raise proprietary or confidentiality concerns for manufacturers.
- The bill relies on recommendations and practices that will be developed in the future, so the exact impacts on industry operations and market structure are uncertain.
- The bill does not itself create new testing standards; it relies on microorganisms already covered by existing FDA finished‑product testing rules but tightens what happens when tests are positive.
- The Secretary’s 90‑day review of each incident must consider not only contamination in production but also the possibility that the sample was contaminated during testing, which could affect how incidents are classified and handled.
Check the details
Key facts
- Requires infant formula manufacturers to notify the Secretary of Health and Human Services within 1 business day when they learn of certain problems, replacing the prior vague “promptly” standard.
- Mandates 1‑business‑day notification to the Secretary whenever finished product testing confirms a positive result for any microorganism covered by FDA’s existing finished‑product testing rules.
- Directs manufacturers to consult with the Secretary on isolating affected product and, if required, to stop distribution and properly dispose of contaminated formula.
- Requires manufacturers to share test results and either isolates or whole‑genome sequence data from confirmed positive samples with the Secretary.
- Obligates the Secretary to respond to a manufacturer within 1 business day after receiving a positive‑test notification to begin investigation and corrective‑action discussions.
- Requires the Secretary, within 90 days of any safety notification, to confirm through documentation that the manufacturer has conducted or is conducting an appropriate root‑cause investigation and corrective action.
- Directs the Secretary to evaluate the laboratory analytical methods used and the potential for cross‑contamination during testing as part of each root‑cause review.
- Requires a progress report within 180 days on implementing recommendations from FDA’s January 2025 report, “Long-Term National Strategy to Increase the Resiliency of the U.S. Infant Formula Market,” including any needed new authorities or resources.
Legislative record
How far the bill has moved
Received by the House
Held at the desk. · May 4, 2026
- Introduced
- Senate Committee
- Senate Floor Vote
- Passed Senate
- 5House Review
- 6Passed Both Chambers
- 7Signed into Law
Contact Congress
Send a message about this bill
Choose your position, add what matters to you, and send a message to the officials who can act on this bill.
Contact your representative